Streptococcus bovis infectious endocarditis and occult gastrointestinal neoplasia: experience with 25 consecutive patients treated surgically

Anthony Alozie 1*, Kerstin Köller 2, Lumi Pose 1, Maximilian Raftis 1, Gustav Steinhoff 1, Bernd Westphal 1, Georg Lamprecht 3 and Andreas Podbielski 2

Abstract

To assess the prevalence of gastrointestinal neoplasia in patients with Streptococcus bovis infectious endocarditis we performed a retrospective cohort analysis of all episodes of S. bovis infectious endocarditis treated at our institution between January 2000 through December 2014. Twenty-five patients were identified for this purpose. 12/25 patients received colonoscopy and 1/25 of the patients was assessed with CT colonography. Of the 13 who underwent colonic assessment, 11 were diagnosed with colonic neoplasms at different stages of development. In the absence of any strong contraindication, gastroenteroscopic evaluation in all patients diagnosed with S. bovis infectious endocarditis should be pursued.

Keywords: Infectious endocarditis, Streptococcus bovis, Colonic neoplasia

Background

Streptococcus bovis (S. bovis), is a commensal inhabitant of the human digestive tract. It may be isolated in up to 35 % of fecal samples from human rectal swab [1]. Since the first remarkable case of the association between an enterococcal infection and colorectal carcinoma presented by McCoy et al. in 1951 and the case control study by Klein et al. over two decades later, the association between S. bovis bacteremia and colorectal neoplasia has been thoroughly well established in the literature [2–4]. The involvement of S. bovis in infectious endocarditis (IE) was put at approximately 6 % [5, 6], which means that IE is another important variable associated with the two phenomena. A systematic review of 31 studies published by Boleij et al. in 2011 found that 65 % of patients infected by S. bovis, in addition to high levels of IE, were also diagnosed with concomitant colorectal neoplasias [7]. The picture became more complex, because genomic analysis revealed that “S. bovis” isolates in fact belonged to at least seven different species or subspecies, i.e. S. galolyticus ssp. galolyticus, S. galolyticus ssp. pasteurianus, S. galolyticus ssp. macedonius, S. infantarius ssp. infantarius, S. infantarius ssp. coli [S. lutentensis], S. alactolyticus, and S. equines. S. galolyticus ssp. is more often encountered in human specimens than the two other species/subspecies. Especially S. galolyticus ssp. galolyticus bacteremias were demonstrated to be associated with colorectal cancer [8, 9]. For reasons of simplicity these strains are furtheron addressed as S. bovis-group isolates.

Reported colorectal neoplasia encompassed adenomas with neoplastic potential, which included tubular, tubulo-villous and villous adenomas. Given this relationship between S. bovis-group bacteremia and colorectal neoplasia, patients with IE treated conservatively or surgically should be promptly evaluated for presence of gastrointestinal neoplasia, since colorectal neoplasia seem to be the preferred colonization site for S. bovis-group strains [7].
Methods

Etiologic diagnosis of *S. bovis*-group IE in 25 patients treated surgically between January 2000 and December 2014 in our heart center was obtained by blood culture and direct valve culture results. Routine 16 sRNA PCR of all intraoperatively excised heart valves from IE patients was introduced from year 2007. Blood culture isolates from external hospitals and those obtained prior to 2007 were not further characterized by molecular genetic methods (8 isolates). However, full-length 16 sRNA PCR gene sequences of blood and heart valve cultures obtained during the later years clearly assigned the strains to *S. galloyticus* subsp *galloyticus* (16) and *Streptococcus lutetiensis* (1). Clinical information was obtained from the patient clinical record. This included presenting symptoms, examination findings, and investigation results from echocardiography, abdominal sonography, computed tomography for general screening purposes and gastroscopy/colonoscopy. Clinical records were reviewed for data regarding demographics, medical co-morbidities, clinical presentation, investigations, surgical interventions, clinical outcome and follow up management. A questionnaire was submitted to each patient's general practitioner to assess current health status. A telephone interview was made if the questionnaire was not returned.

Diagnosis of IE was established by a team of cardiologists, heart surgeons, microbiologists and pathologists applying the modified Duke criteria [10].

Microbiology

Processing of blood cultures followed the established standards of the German Society for Hygiene and Microbiology (DGHM). The microbiology laboratory of Rosstock University Medicine is accredited according to DIN EN ISO 15183 for these tests as well as for the PCR examinations. DNA extraction was performed with the Qiagen DNA Mini Kit (QIAGEN, Hilden, Germany) according to the manufacturer's protocol. Nucleic acid concentration was measured using a biophotometer (Eppendorf, Hamburg, Germany). For 16S rDNA PCR primers, 16S_27 and 16S_907 and polymerase moltaq (molzym) were utilized [11, 12]. The following reaction conditions were chosen: (1) 15 min at 94 °C; (2) 30× [1 min at 94 °C, 1 min at 50 °C, 1 min at 72 °C]; (3) 5 min at 72 °C [11, 12]. PCR products were determined by gel electrophoresis, purified with the NAT CLEAN-UP/NUCLEOSPIN® EXTRACT II (Machery-Nagel, Düren, Germany) and subsequently sent to Microsynth Sequencing Device (Göttingen, Germany) for the actual sequencing reaction. Sequence analysis was performed using NCBI nucleotide blast search (http://www.ncbi.nlm.nih.gov), resulting in identification of various species of the *S. bovis*-group (Table 1).

Results

Twenty-five *S. bovis*-group IE episodes with available patient clinical data were identified. These were in 23 males and 2 females. Mean age was 63.9 (range 40–84 years).

A definite IE according to the duke criteria was established preoperatively in all patients and confirmed by post surgical histological and microbiological processing of every single excised heart valve. Sixteen of the IE episodes were caused by *S. galloyticus* subsp *galloyticus* and the remaining nine cases by 1 *S. lutetiensis* and 8 isolates of the *S. bovis*-group with no further differentiation.

Of the 25 patients examined, 13 received gastroenteroscopic assessment for gastrointestinal neoplasia post surgery by means of gastroscopy, colonoscopy and CT colonography. Of these 13 patients, 11 had gastrointestinal neoplasia (84.6 %). Detailed evaluation of gastroenteroscopic findings in 11 of the 13 patients assessed are depicted in Table 1. One patient with ethyl toxic liver cirrhosis and esophagus varices grade III° at time of surgery who refused colonoscopy was diagnosed with colo-sigmoid carcinoma 6 years later.

Discussion

The clinical relationship between *S. bovis*-group bacteremia and underlying gastrointestinal malignancies or premalignant adenomatous polyps has been well known for many years [2, 3]. Although this association has huge clinical implications for both patients and physicians being entrusted with further management of these patients both during major illnesses and thereafter, we found unsatisfactory awareness of this among family doctors. This is reflected in the unacceptably low number of patients we observed in this study obtaining gastroenteroscopic evaluation after hospital discharge. Those patients who did obtain gastroenteroscopic evaluation, only received this during their hospital stay. Of those who were discharged without gastroenteroscopic evaluation, lack of compliance was often noted, but the remaining patients were probably not followed up as required. One patient in our series was diagnosed with colonic adenocarcinoma 6 years later, after he had refused gastrointestinal evaluation post surgery. We speculate that this occurrence could probably have been prevented if a colonoscopy had been obtained in the first place.

The rate of patients undergoing colonic evaluation in our study (52 %) did not significantly differ from those reported in previous literature [13, 14] (70 and 50 %) although it was far lower than those reported by Ballet et al. (81 %) and Tripod et al. (96 %) [15, 16]. However, the prevalence of colonic malignancies or premalignancies we found in those patients subjected to gastroenteroscopic evaluation 13/25 is in between those reported in
## Table 1 Patients baseline characteristics, gastrointestinal findings and underlying conditions

| Pat. nr | Age/sex | Year | Bio-type | IE | Bowel evaluation | Findings | Underlying conditions |
|---------|---------|------|----------|----|-----------------|----------|----------------------|
| 1       | 64/m    | 2003 | S. bovis |    | Gastroscopy, colonoscopy | Two 1–1.5 cm tubular sessile adenoma, intermediate dysplasia | CLL, microcytic anemia, BPH, carcinoma of prostate 3 years later |
| 2       | 49/m    | 2004 | S. bovis |    | Declined        | Colosigmoid adenocarcinoma 5 years later | Alcohol toxic liver cirrhosis, esophagus varices III° |
| 3       | 69/m    | 2004 | S. bovis |    | Gastroscopy, colonoscopy | Gastritis | Gastritis, colostoma (post sigma ischemia) |
| 4       | 49/m    | 2005 | S. gallolyticus subsp. gallolyticus |    | Colonoscopy     | Two 1 cm tubular colon adenoma low grade dysplasia | None |
| 5       | 64/m    | 2007 | S. gallolyticus subsp. gallolyticus |    | Colonoscopy     | Five 1–2 cm polyps, with high grade suspicion for coecum carcinoma | None |
| 6       | 72/m    | 2007 | S. gallolyticus subsp. gallolyticus |    | No colonoscopy  | – | None |
| 7       | 53/m    | 2008 | S. gallolyticus subsp. gallolyticus |    | No colonoscopy  | – | None |
| 8       | 70/m    | 2008 | S. gallolyticus subsp. gallolyticus |    | No colonoscopy  | – | Hepatitis C, PEG interferone, dialysis |
| 9       | 73/m    | 2009 | S. gallolyticus subsp. gallolyticus |    | Colonoscopy     | 2 × 2 cm tubular Polyps, high grade suspicion for carcinoma 2014 | Liver cirrhosis, psoriasis |
| 10      | 54/m    | 2009 | S. gallolyticus subsp. gallolyticus |    | Gastroscopy, colonoscopy | Pangastritis, 2 × broad based colonic adenoma | Pangastritis |
| 11      | 70/m    | 2009 | S. gallolyticus subsp. gallolyticus |    | Lost to follow up | – | Spinal abscess surgery |
| 12      | 57/m    | 2009 | S. gallolyticus subsp. gallolyticus |    | Colonoscopy     | Diverticulosis of small/large intestine | |
| 13      | 74/m    | 2010 | S. gallolyticus subsp. gallolyticus |    | Colonoscopy/gastroscopy | Broad based stomach Polyp | Spondylodiscitis |
| 14      | 66/m    | 2010 | S. gallolyticus subsp. gallolyticus |    | No colonoscopy  | – | None |
| 15      | 77/m    | 2011 | S. bovis  |    | CT colonography | Normal | Steatosis hepatitis, BPH |
| 16      | 48/m    | 2012 | S. gallolyticus subsp. gallolyticus |    | Colonoscopy     | 4 Colonic polyps, 7–15 mm; stomach poly, mucus-producing tumor left colonic flexure | Liver cirrhosis child B, esophagus varices II° |
| 17      | 60/m    | 2012 | S. gallolyticus subsp. gallolyticus |    | No colonoscopy  | – | None |
| 18      | 63/f    | 2012 | S. gallolyticus subsp. gallolyticus |    | No colonoscopy  | – | None |
| 19      | 68/m    | 2013 | S. gallolyticus subsp. gallolyticus |    | Colonoscopy     | Colonic polyp | None |
| 20      | 57/m    | 2013 | S. gallolyticus subsp. gallolyticus |    | No colonoscopy  | – | Hepatitis B, chronic alcohol abuse |
| 21      | 84/m    | 2000 | S. bovis  |    | Colonoscopy     | Multiple colonic polyps up to 1 cm each | Cholecystolithiasis, splenomegaly |
| 22      | 65/m    | 2000 | S. bovis  |    | No colonoscopy  | – | Ethyl toxic liver insufficiency, esophagus varices III° |
| 23      | 78/m    | 2014 | S. lutetiensis |    | Colonoscopy     | Colonic and rectal polyps resected | None |
| 24      | 40/m    | 2000 | S. bovis  |    | No colonoscopy  | – | Hepatitis C and HIV |
| 25      | 74/f    | 2007 | S. bovis  |    | No colonoscopy  | – | Dialysis due to cystic kidney disease |

CLL chronic lymphocytic leukemia, BPH benign prostate hyperplasia, PEG-interferone pegylated interferone
other studies, with a similar number of patients subjected to colonic evaluation (33% Coffey and 86% Vaska) [13, 14]. *S. gallolyticus* subsp. *gallolyticus* has a median colorectal neoplasia prevalence among *S. bovis* bacteraemia patients of 60–67% but only 25% prevalence in the general population that underwent colonoscopy, showing the clear association of *S. gallolyticus* subsp. *gallolyticus* with colorectal neoplasia [9]. Current medical recommendations therefore advise to perform colonoscopy for any patient diagnosed with *S. gallolyticus* subsp. *gallolyticus* bacteraemia due to the 2/3 association of *S. gallolyticus* subsp. *gallolyticus* with colorectal neoplasia and 21% yielding de facto colorectal carcinomas [9].

Of all 13 patients in our study that obtained colonic evaluation, 11 had colonic malignancies or premalignancies (84.6%). Since our study is neither randomized nor prospective in nature, we cannot exclude the possibility that these results are obtained by chance. However, our results are in line with other studies with high prevalence of malignancies or premalignacies of the colon with the same setting [13]. We admit that there is a wide range between reported prevalence of gastrointestinal neoplasia during *S. bovis* bacteraemia, ranging from 6% in the retrospective analysis presented by Pigrau et al. to 86% as reported in a retrospective study by Vaska et al. [17]. This may be partly due to the retrospective nature of these studies, as a limited amount of patients underwent bowel evaluation after episodes of bacteraemia.

**Conclusion**

Adenomatous polyps are tumors of benign neoplastic epithelium with variable potential for malignancy. The adenoma-carcinoma sequence is well known and it is accepted that more than 95% of colorectal cancers arise from adenomas [18]. Though, to date there has been no satisfactory explanation regarding the pathophysiological mechanism behind this association. We admit that we were not able to provide precise differentiation between all species and subspecies, a factor necessary for correct risk assessment of every diagnosis. In consideration of this fact, we strongly advocate subtyping of every single case of *S. bovis* bacteraemia and gastroenteroscopic assessment in all patients diagnosed and treated for *S. bovis*-group IE during or soon after their index admission, as 84.4% of our patients who obtained this assessment had colorectal neoplasia.

**Authors’ contributions**

AA drafted the manuscript and collected clinical data. KK and AP carried out microbiological analysis including PCR and sequencing analysis and drafted part of the manuscript. LP and MR collected clinical data. GS and BW participated in coordination and design of the study. GL carried out gastroenteroscopic assessment of the patients. All authors read and approved the final manuscript.

**Author details**

1. Department of Cardiac Surgery, University Heart Center Rostock, Schillingallee 35, 18057 Rostock, Germany.
2. Institute of Medical Microbiology, Virology and Hygiene, University Hospital Rostock, Schillingallee 70, 18055 Rostock, Germany.
3. Zentrum für Innere Medizin, Klinik II - Abteilung für Gastroenterologie, Ernst-Heydemann-Str. 6, 18057 Rostock, Germany.

**Competing interests**

The authors declare that they have no competing interests.

**Received: 18 June 2015 Accepted: 23 September 2015 Published online: 15 October 2015**

**References**

1. Lopes PG, Cantarelli IV, Agnes G, Costabeber AM, d’Azevedo PA. Novel real-time PCR assays using TadMan mini grove binder probes for identification of fecal carriage of *Streptococcus bovis*/Streptococcus equinus complex from rectal swab specimens. J Clin Microbiol. 2014;52:974–9.
2. McCoy WC, Mason JM. 3rd. Enterococcal endocarditis associated with carcinoma of the sigmoid; report of a case. J Med Assoc State Ala. 1951;21:162–6.
3. Klein RS, Recco RA, Catalano MT, Edberg SC, Casey JI, Steigbigel NH. Association of *Streptococcus bovis* with carcinoma of the colon. N Engl J Med. 1977;297:800–2.
4. Bolej J, Tjalsma H. The itinerary of *Streptococcus gallolyticus* infection in patients with colorectal malignant disease. Lancet Infect Dis. 2013;13:719–24.
5. Moreillon P, Que YA. Infective endocarditis. Lancet. 2004;363:139–49.
6. Murdoch DR, Corey GR, Hoen B, Miró JM, Fowler VG Jr, Bayer AS, Karchmer AW, Olaire X, Pappas PA, Moreillon P, Chambers ST, Chu VH, Falcó V, Holland DJ, Jones P, Klein JL, Raymond NJ, Read KM, Trippodi MF, Utili R, Wang A, Woods CW, Cabell CH, International Collaboration on Endocarditis-Prospective Cohort Study (ICE-PCS) Investigators. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study. Arch Intern Med. 2009;169:463–73.
7. Bolej J, van Gelder MM, Swinkels DW, Tjalsma H. Clinical importance of *Streptococcus gallolyticus* infection among colorectal cancer patients: systematic review and meta-analysis. Clin Infect Dis. 2011;53:870–8.
8. Jans C, Meile L, Lacroix C, Stevens MJ. Genomics, evolution, and molecular epidemiology of the *Streptococcus bovis*/Streptococcus equinus complex (SBSEC). Infect Genet Evol. 2015;33:419–36.
9. Corredor J, García-Pais MJ, Coria A, Rabuñal R, García-Farre F, Pita J, Rodríguez-Macías A, Blanco M, López-Roses I, López-Álvarez MJ, Alonso-García MP. Differences between endocarditis caused by *Streptococcus bovis* and *Enterococcus* spp. and their association with colorectal cancer. Eur J Clin Microbiol Infect Dis. 2015;34:1657–65.
10. Li JS, Sexton DJ, Mick N, Nettles R, Fowler VG Jr, Ryan T, Bashore T, Corey GR. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis. 2000;30:633–8.
11. Zheng D, Alf M, Stahl D, Raskin L. Characterization of universal small subunit rRNA hybridization probes for quantitative molecular microbial ecology studies. Appl Environ Microbiol. 1996;62:4504–13.
12. Weisburg WG, Barns SM, Pelletier DA, Lane DJ. 16S ribosomal DNA amplification for phylogenetic study. J Bacteriol. 1991;173:697–703.
13. Vaska VL, Faoagali JL. *Streptococcus bovis* bacteraemia: identification within organism complex and association with endocarditis and colorectal malignancy. Pathology. 2009;41:182–6.
14. Coffey S, Nadarasa K, Pan A, van der Linden A, Chu J, Schultz M. The increasing incidence of *Streptococcus bovis* endocarditis and bacteraemia: a case series from 1997 to 2010. Int J Cardiol. 2012;161:111–3.
15. Ballet M, Gevigney G, Garé JP, Delahaye F, Etienne J, Delahaye JP. Infective endocarditis due to *Streptococcus bovis*. A report of 53 cases. Eur Heart J. 1995;16:1975–80.

16. Tripodi MF, Adinolfi LE, Ragone E, Durante Mangoni E, Fortunato R, Irarussi D, Ruggiero G, Utili R. *Streptococcus bovis* endocarditis and its association with chronic liver disease: an underestimated risk factor. Clin Infect Dis. 2004;38:1394–400.

17. Pigrau C, Lorente A, Pahissa A, Martinez-Vazquez JM. *Streptococcus bovis* bacteremia and digestive system neoplasms. Scand J Infect Dis. 1988;20:459–60.

18. Bujanda L, Cosme A, Gil I, Arenas-Mirave JL. Malignant colorectal polyps. World J Gastroenterol. 2010;16:3103–11.